Who Paid My Doc
Fensolvi
Drug Central Precocious Puberty (CPP)
NDC 62935-153-50
General payments
$458,928
Research payments
$39,465
Through program year 2025, $458,928 in general payments and $39,465 in research payments were reported against Fensolvi (Central Precocious Puberty (CPP)).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $167,142 | 1,263 |
| 2025 | Research | $39,465 | 3 |
| 2023 | General | $78,778 | 1,002 |
| 2022 | General | $122,229 | 1,184 |
| 2021 | General | $55,344 | 508 |
| 2020 | General | $35,435 | 160 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 39 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 43 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,117 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.